American Society of Clinical Oncology

SHERPA: White

People

  1. Kris
    Kris
  2. Riely
    Riely
  3. Ladanyi
    Ladanyi
  4. Miller
    Miller
  5. Arcila
    Arcila
  6. D'Angelo
    D'Angelo
  7. Paik
    Paik
  8. Chaft
    Chaft
  9. Rusch
    Rusch
  10. Adusumilli
    Adusumilli

Groups

  1. Department of Medicine (18)
  2. Solid Tumor Oncology Division (18)
  3. Thoracic Oncology (18)
  4. GSK Faculty (7)
  5. Tow Center for Developmental Oncology (TCDO) (6)
  6. Human Oncology and Pathogenesis Program (5)
  7. Hematologic Malignancies, Division of (4)
  8. Sarcoma Service (3)
  9. Surgery (3)
  10. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (2)
Search Within
  1. "2011"
  2. "Thoracic Oncology"
Formats
  1. Meeting Abstract (12)
  2. Journal Article (6)
Groups
  1. Department of Medicine (18)
  2. Solid Tumor Oncology Division (18)
  3. Thoracic Oncology (18)
  4. GSK Faculty (7)
  5. Tow Center for Developmental Oncology (TCDO) (6)
  6. Human Oncology and Pathogenesis Program (5)

More Groups

People
  1. Mark Kris (14)
  2. Gregory Riely (10)
  3. Camelia Sima (5)
  4. Marc Ladanyi (5)
  5. Vincent Miller (5)
  6. Geoffrey Oxnard (3)

More People

Years
  1. 2011 (18)
Publications
  1. Journal of Clinical Oncology (17)
  2. Journal of Oncology Practice (1)

Results (18)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Can we really treat patients older than age 70 with a chemotherapy doublet for non-small cell lung cancer (NSCLC)?
    Meeting Abstract

    Zauderer, M. G.; Sima, C. S.; Korc-Grodzicki, B.; Kris, M. G.; Krug, L. M.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC)
    Meeting Abstract

    Kris, M. G.; Johnson, B. E.; Kwiatkowski, D. J.; Iafrate, A. J.; Wistuba, I. I.; Aronson, S. L.; Engelman, J. A.; Shyr, Y.; Khuri, F. R.; Rudin, C. M.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls
    Meeting Abstract

    Shaw, A. T.; Yeap, B. Y.; Solomon, B. J.; Riely, G. J.; Iafrate, A. J.; Shapiro, G.; Costa, D. B.; Butaney, M.; Ou, S. I.; Maki, R. G.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel in pretreated patients (pts) with metastatic non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Riely, G. J.; Gettinger, S. N.; Stoller, R. G.; Gabrail, N. Y.; Dy, G. K.; Weiss, G. J.; Tunkey, C.; Skliris, G.; Strychor, S.; Dunbar, J.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Clinical, pathologic, and molecular characteristics of patients with non-small cell lung cancer harboring mutations in PIK3CA
    Meeting Abstract

    Pietanza, M. C.; Arcila, M. E.; Chaft, J. E.; Zakowski, M. F.; Ladanyi, M.; Riely, G. J.; Kris, M. G.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Maintained sensitivity to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant lung cancers that recur after adjuvant TKI
    Meeting Abstract

    Oxnard, G. R.; Janjigian, Y. Y.; Arcila, M. E.; Kris, M. G.; Ladanyi, M.; Azzoli, C. G.; Miller, V. A.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Response to EGFR TKIs in never smokers with stage IV EGFR mutant squamous cell carcinoma of the lung (SQCC)
    Meeting Abstract

    Paik, P. K.; Rekhtman, N.; Riely, G. J.; Miller, V. A.; Ladanyi, M.; Kris, M. G.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Randomized, double-blinded, phase II trial of a WT1 peptide vaccine as adjuvant therapy in patients with malignant pleural mesothelioma (MPM)
    Meeting Abstract

    Krug, L. M.; Tsao, A. S.; Kass, S.; Rusch, V. W.; Travis, W. D.; Panageas, K.; Adusumili, P. S.; Kris, M. G.; Maslak, P. G.; Scheinberg, D. A.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m(2) for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
    Meeting Abstract

    Fury, M. G.; Sherman, E. J.; Lisa, D. M.; Agarwal, N.; Algazy, K. M.; Brockstein, B.; Langer, C. J.; Lim, D.; Mehra, R.; Rajan, S. K.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005
    Meeting Abstract

    Crinò, L.; Kim, D.; Riely, G. J.; Janne, P. A.; Blackhall, F. H.; Camidge, D. R.; Hirsh, V.; Mok, T.; Solomon, B. J.; Park, K.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save